{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T07:44:51Z","timestamp":1788335091004,"version":"build-2803163510"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2022,3,15]]},"abstract":"<jats:sec xml:lang=\"en\">\n            <jats:title>Background<\/jats:title>\n            <jats:p xml:lang=\"en\">Guideline recommendations are the accepted reference for selection of therapies for rhythm control of atrial fibrillation (AF). This study was designed to understand physicians\u2019 treatment practices and adherence to guidelines.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Methods and Results<\/jats:title>\n            <jats:p xml:lang=\"en\">The AIM\u2010AF (Antiarrhythmic Medication for Atrial Fibrillation) study was an online survey of clinical cardiologists and electrophysiologists that was conducted in the United States and Europe (N=629). Respondents actively treated \u226530 patients with AF who received drug therapy, and had received or were referred for ablation every 3\u00a0months. The survey comprised 96 questions on physician demographics, AF types, and treatment practices. Overall, 54% of respondents considered guidelines to be the most important nonpatient factor influencing treatment choice. Across most queried comorbidities, amiodarone was selected by 60% to 80% of respondents. Other nonadherent usage included sotalol by 21% in patients with renal impairment; dofetilide initiation (16%, United States only) outside of hospital; class Ic agents by 6% in coronary artery disease; and dronedarone by 8% in patients with heart failure with reduced ejection fraction. Additionally, rhythm control strategies were frequently chosen in asymptomatic AF (antiarrhythmic drugs [AADs], 35%; ablation, 8%) and subclinical AF (AADs, 38%; ablation, 13%). Despite guideline algorithms emphasizing safety first, efficacy (48%) was selected as the most important consideration for AAD choice, followed by safety (34%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p xml:lang=\"en\">Despite surveyed clinicians recognizing the importance of guidelines, nonadherence was frequently observed. While deviation may be reasonable in selected patients, in general, nonadherence has the potential to compromise patient safety. These findings highlight an underappreciation of the safe use of AADs, emphasizing the need for interventions to support optimal AAD selection.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/jaha.121.023838","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T10:34:18Z","timestamp":1646390058000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":24,"title":["AIM\u2010AF: A Physician Survey in the United States and Europe"],"prefix":"10.1161","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2536-2871","authenticated-orcid":false,"given":"A. John","family":"Camm","sequence":"first","affiliation":[{"name":"St George\u2019s University London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2806-3903","authenticated-orcid":false,"given":"Carina","family":"Blomstr\u00f6m\u2010Lundqvist","sequence":"additional","affiliation":[{"name":"Department of Medical Science &amp; Cardiology Uppsala University Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9820-4815","authenticated-orcid":false,"given":"Giuseppe","family":"Boriani","sequence":"additional","affiliation":[{"name":"University of Modena &amp; Reggio Emilia Modena Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Goette","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Intensive Care Medicine St Vincenz Hospital Paderborn Paderborn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7189-1638","authenticated-orcid":false,"given":"Peter R.","family":"Kowey","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Medical College at Thomas Jefferson University Philadelphia PA"},{"name":"Lankenau Heart Institute Philadelphia PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose L.","family":"Merino","sequence":"additional","affiliation":[{"name":"La Paz University Hospital, Idipaz, Autonoma University Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0772-2404","authenticated-orcid":false,"given":"Jonathan P.","family":"Piccini","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute Duke University Durham NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6282-6420","authenticated-orcid":false,"given":"Sanjeev","family":"Saksena","sequence":"additional","affiliation":[{"name":"Rutgers Robert Wood Johnson Medical School Piscataway NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5505-1866","authenticated-orcid":false,"given":"James A.","family":"Reiffel","sequence":"additional","affiliation":[{"name":"Columbia University New York NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.22.8.983"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01236-6"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198204293061703"},{"key":"e_1_3_2_5_2","first-page":"195","article-title":"Atrial fibrillation: the current epidemic","volume":"14","author":"Morillo CA","year":"2017","unstructured":"Morillo CA, Banerjee A, Perel P, Wood D, Jouven X. Atrial fibrillation: the current epidemic. J Geriatr Cardiol. 2017;14:195\u2013203. doi: 10.11909\/j.issn.1671\u20105411.2017.03.011","journal-title":"J Geriatr Cardiol"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa612"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/cir.0000000000000041"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000665"},{"key":"e_1_3_2_9_2","first-page":"3028","article-title":"Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study","volume":"99","author":"L\u00e9vy S","year":"1999","unstructured":"L\u00e9vy S, Maarek M, Coumel P, Guize L, Lekieffre J, Medvedowsky JL, Sebaoun A. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation. 1999;99:3028\u20133035.","journal-title":"The College of French Cardiologists. Circulation"},{"key":"e_1_3_2_10_2","unstructured":"U.S. Food and Drug Administration (FDA) . Dofetilide capsules (Rx only) [US label information on Dofetilide]. Published March 2016. Accessed June 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/207058Orig1s000lbl.pdf"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/jhm.445"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","unstructured":"Infinium Global Research . Cardiac Ablation Market: Global Industry Analysis Trends Market Size and Forecasts up to 2025. SDKI. Published November 2020. Accessed June 2021. https:\/\/www.sdki.jp\/reports\/cardiac\u2010ablation\u2010market\/103783","DOI":"10.1016\/j.focat.2021.08.003"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-11-126"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.2196\/jmir.6318"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/0163278713496630"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-034778"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-016-0999-4"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.044109"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021328"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2008.158931"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.07.040"},{"key":"e_1_3_2_22_2","first-page":"658","article-title":"For the Investigators of the Hot Cafe Polish Study. Functional status with rhythm\u2010 versus rate\u2010control strategy for persistent atrial fibrillation","volume":"128","author":"Kosior DA","year":"2018","unstructured":"Kosior DA, Szulc M, Rosiak M, Rabczenko D, Opolski G. For the Investigators of the Hot Cafe Polish Study. Functional status with rhythm\u2010 versus rate\u2010control strategy for persistent atrial fibrillation. Pol. Arch Intern Med. 2018;128:658\u2013666. doi: 10.20452\/pamw.4316","journal-title":"Pol. Arch Intern Med"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.113.000806"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2019.10.002"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/HCQ.0000000000000011"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2019.10.005"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2019422"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.117.005051"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.120.008961"},{"key":"e_1_3_2_30_2","first-page":"CD005049","article-title":"Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation","volume":"9","author":"Valembois L","year":"2019","unstructured":"Valembois L, Audureau E, Takeda A, Jarzebowski W, Belmin J, Lafuente\u2010Lafuente C. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2019;9:CD005049. doi: 10.1002\/14651858.CD005049.pub5","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2018.06.018"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.02.601"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10840-021-00942-y"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi505"}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.121.023838","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T11:40:25Z","timestamp":1715600425000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.121.023838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,15]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,3,15]]}},"alternative-id":["10.1161\/JAHA.121.023838"],"URL":"https:\/\/doi.org\/10.1161\/jaha.121.023838","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,15]]},"assertion":[{"value":"2021-09-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e023838"}}